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Peroxisome proliferator-activated receptors (PPAR)
are members of a nuclear receptor superfamily,
which were initially described in the context of fatty
acid degradation and adipocyte differentiation. In
this study we tested the hypothesis that peroxisome
proliferator-activated receptor activation also con-
trols in¯ammation. In an in vitro model with human
keratinocytes in¯ammation was mimicked by irradi-
ation with ultraviolet B light (150 mJ per cm2).
Activators for PPAR-a (WY-14,643, clo®brate) were
shown to reverse ultraviolet-B-light-mediated
expression of in¯ammatory cytokines (interleukin-6,
interleukin-8). An activator preferentially for PPAR-
b (beza®brate) did not show prominent effects on
interleukin-6 and interleukin-8 expression. The anti-
in¯ammatory action of WY-14,643 on skin cells was
further demonstrated by in vivo testings in which
topically applied WY-14,643 markedly increased the
minimal erythema dose in ultraviolet-B-irradiated
skin. Additionally, it was shown that ultraviolet B
irradiation led to a decrease of all three peroxisome
proliferator-activated receptor subsets at the mRNA
level. Also transactivation of peroxisome proliferator
response element was attenuated by ultraviolet B
irradiation. The downregulation of peroxisome pro-
liferator-activated receptors by ultraviolet B irradi-
ation provides a possible mechanism that leads to
exaggerated and prolonged in¯ammation. This work
suggests the possibility of PPAR-a activators as
novel nonsteroidal anti-in¯ammatory drugs in the
topical treatment of common in¯ammatory skin dis-
eases such as atopic dermatitis, psoriasis, and photo-
dermatitis. Key words: erythema/irradiation/PPAR/
WY-14,643. J Invest Dermatol 117:1430±1436, 2001
P
eroxisome proliferator-activated receptors (PPAR) be-
long to the nuclear steroid hormone receptor super-
family, which are involved in transduction of a variety of
environmental, nutritional, and in¯ammatory signals
into a de®ned set of cellular responses (Lemberger et al,
1996). At present, three subsets of PPAR isoforms, a, b (PPAR-d,
NUC1, or FAAR), and g, have been identi®ed (Dreyer et al, 1992;
Chen et al, 1993; Lemberger et al, 1996). Activation of PPAR was
®rst observed with synthetic compounds that induce peroxisome
proliferation, such as hypolipidemic drugs of the ®brate family
(Issemann and Green, 1990; Goettlicher et al, 1992). In particular,
PPAR-a has been identi®ed as a regulator of genes that control
fatty acid degradation (b- and w-oxidation) (Schoonjans et al,
1996a). Interestingly in skin keratinocytes, PPAR-a activation has
offered stimulatory effects on differentiation and on the develop-
ment of the epidermal permeability barrier (Hanley et al, 1997,
1998; Koemueves et al, 2000a, b). The authors have described
induction of involucrin and transglutaminase combined with a
decline of proliferation induced by PPAR-a activators. These
observations give future perspectives on treatment of skin diseases
with disturbed differentiation patterns, such as psoriasis. Besides the
activation of PPAR by synthetic agents, recently, metabolites of
arachidonic acid have been identi®ed as naturally occurring ligands
for PPAR (Schoonjans et al, 1996b). In particular, leukotriene B4
(LTB4) for PPAR-a and prostaglandin J2 for PPAR-g have been
identi®ed (Krey et al, 1997). The contribution of arachidonic acid
metabolites to PPAR activation suggests the relevance of PPAR in
in¯ammation. In this context, Jiang et al (1998) have shown that
activation of PPAR-g suppresses the expression of pro-in¯amma-
tory cytokines in monocytes. In addition, PPAR-g activation was
®rst described in adipocyte differentiation (Chawla et al, 1994;
Tontonoz et al, 1994), which was opposed by several pro-
in¯ammatory cytokines (Torti et al, 1989; Jiang et al, 1998). The
role of PPAR-b is still an enigma.
This study tested the putative anti-in¯ammatory potency of
activators that predominately activate either PPAR-a or PPAR-b
in human skin cells. It was demonstrated that an activator of
PPAR-a offered clear anti-in¯ammatory effects both in vitro and
in vivo. These observations may aid in new therapeutic strategies in
the treatment of various in¯ammatory skin diseases. Therefore,
PPAR activators are new members within a class of compounds
that offer anti-in¯ammatory properties that avoid the negative side-
effects of steroids (Paul and Ho, 1998; Ruzicka et al, 1999).
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MATERIALS AND METHODS
Cell culture and cell treatment Spontaneously immortalized human
keratinocyte cell line (HaCaT) (a generous gift by Prof. Fusenig, German
Cancer Research Institute, Heidelberg, Germany) was cultured in
carbonate buffered Hank's medium with 5% fetal bovine serum and 1%
penicillin±streptomycin (Biochrom, Berlin, Germany) at 37°C in a 5%
CO2 atmosphere. The medium was renewed twice a week. The
following PPAR activators were used: beza®brate (Sigma, Taufkirchen,
Germany), clo®brate (Sigma, Taufkirchen, Germany), and WY-14,643
(Biomol, Hamburg, Germany). PPAR activators were solubilized in
dimethyl sulfoxide (DMSO) and than further diluted in culture medium.
Tumor necrosis factor a (TNF-a; Cell Concepts, Umkirch, Germany)
was added to the cultures at 10 ng per ml.
Ultraviolet (UV) B irradiation of cultured cells The UVB radiation
source used was a Waldmann 3003 K light cabin (Waldmann, Villingen-
Schurenningen, Germany), emitting 2.5 mW per cm2 broad-band UVB
(peak 310±315 nm) at 25 cm distance. Cells were exposed with 150 mJ
per cm2 UVB. PPAR activators were added to the culture medium 4 h
prior UVB treatment. During exposure medium was replaced by
phosphate-buffered saline containing the PPAR activators.
Consecutively, medium supplemented with the PPAR activators was
added back to the cells. RNA and proteins were extracted after the
indicated time intervals.
Reverse transcriptase competitive multiplex polymerase chain
reaction (PCR) Internal standards (IST) for reverse transcriptase
competitive multiplex PCR were generated according to Celi et al
(1993). The regulation of transcript levels using glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as reference was performed as
described previously (Kippenberger et al, 1998; Loitsch et al, 1999).
Brie¯y, 6 h after UVB irradiation total RNA was extracted using Trizol
reagent (Gibco, Karlsruhe, Germany). Three micrograms of total RNA
were reverse transcribed by using Superscript reverse transcriptase
(Gibco, Karlsruhe, Germany) according to the manufacturer's
instructions. Table I shows the primer sequences used and the expected
product lengths. Products derived from primer combination A/IST were
cloned into the pGEM-T-vector (Promega, Mannheim, Germany) and
propagated in JM109 competent cells. Several insert-containing colonies
were selected to be cultured. Plasmid extraction was carried out with
Qiagen plasmid mini kit (Qiagen, Hilden, Germany) and molecule
concentration was calculated. For reverse transcriptase competitive
multiplex PCR ISTs of GAPDH (GenBank M33197), PPAR-a
(GenBank Y07619), PPAR-b (GenBank NM_006238), PPAR-g
(GenBank D83233), interleukin-6 (IL-6) (GenBank M54894), and IL-8
(GenBank M28130) were diluted to the cDNAs of interest and
coampli®ed along with the wildtype target. By agarose gel
electrophoresis the IST-derived signals could be discriminated from
referring wildtype signals. The gray level of each signal was determined
and analyzed using 1D Image Analysis Software (Kodak, Rochester, NY,
USA). By relating IST signals to the corresponding wildtype signals a
regulation of gene transcription could be evaluated.
Enzyme-linked immunosorbent assay (ELISA) of pro-
in¯ammatory cytokines (IL-6, IL-8) After 24 h incubation with or
without irradiation, in the presence or absence of PPAR activators, cell-
free supernatants were obtained and assayed for human IL-6 and IL-8,
using commercial ELISA test kits (Cell Concepts, Umkirch, Germany;
Promocell, Heidelberg, Germany). Additionally, cells were stimulated
with 10 ng per ml TNF-a for 24 h and tested for IL-6 and IL-8 release.
The lower limit of detection for the IL-6 ELISA was 3.4 pg per ml and
for the IL-8 ELISA 10 pg per ml. Culture medium alone, and DMSO
controls, respectively, had no effect on IL-6 and IL-8 release.
DNA synthesis HaCaT cells were cultivated in microwell plates at a
density of 2 3 104 cells per well. Cells were exposed for 24 h to the
different PPAR activators at the indicated concentrations. For the last 4 h
cells were pulsed with 5-bromo-2¢-deoxyuridine (BrdU). Subsequently,
the incorporation rate of BrdU was determined using a commercial
enzyme-linked immunosorbent assay kit (Roche). Brie¯y, cells were
®xed and immune complexes were formed using peroxidase-coupled
BrdU antibodies. A colorimetric reaction with tetramethylbenzidine as
substrate gives rise to a reaction product measured at 450 nm in a
scanning multiwell spectrophotometer (ELISA reader).
Cytotoxicity Cell death and cell lysis were quanti®ed using the
cytotoxicity detection kit (Roche, Basel, Switzerland), which is based on
release of lactate dehydrogenase from damaged cells. Brie¯y, HaCaT cells
were cultivated for 24 h with different PPAR activators at the indicated
concentrations. In a ®rst step cell-free supernatants were incubated with
NAD+, which becomes reduced by lactate dehydrogenase to NADH/
H+. In the second step NADH/H+ reduces a yellow tetrazolium salt to a
red-colored formazan salt. The amount of red color is proportional to
the number of lyzed cells. For quantitation the absorbance of the
reaction product was measured at 490 nm using a scanning multiwell
spectrophotometer (ELISA reader).
PPRE transactivation assay Expression plasmid containing ®re¯y
luciferase driven by three copies of PPRE was kindly provided by Dr. S.
Michel (Galderma, Sophia Antipolis, France). Transactivation assays were
performed using the Dual-Luciferase Reporter Assay System (Promega,
Mannheim, Germany). Brie¯y, HaCaT cells were cotransfected by
electroporation with PPRE±®re¯y luciferase plasmids and renilla
luciferase-containing plasmids driven by an SV40 promoter. The latter
served to monitor transfection ef®ciency. After transfection, cells were
plated and allowed to attach for 24 h. Consecutively, cells were
irradiated and further incubated for 24 h in the presence or absence of
200 mM WY-14,643. After cell lysis, activity of both luciferases was
detected separately using a luminometer (Berthold, Bad Wildbad,
Germany).
In vivo testing The anti-in¯ammatory potency of a PPAR-a activator
was tested by ®ve volunteers by determination of the minimal erythema
dose (MED), de®ned as the smallest dose of UVB to result in a just-
detectable erythema 24 h after irradiation with UVB. 5% (wt/wt) WY-
14,643 in Dorithin cream (Astra Medica, Vienna, Austria) was applied
occlusively for 4 h to the right volar aspects of the forearms of the ®ve
volunteers, whereas Dorithin alone was applied to the left forearm for
Table I. Primer combinations used for generation of competitors and wild-type products
GAPDH-wt GAPDH-A 5'-ATC TTC CAG GAG CGA GAT CC-3' GAPDH-B: 5'-ACC ACT GAC ACG TTG GCA GT-3' 502bp
GAPDH-IST GAPDH-A: 5'-ATC TTC CAG GAG CGA GAT CC-3' GAPDH-IST: 5'- ACC ACT GAC ACG TTG GCA GTA
GTA GAG GCA GGG ATG ATG T -3'.
427bp
PPARa-wt PPAR-a-A: 5'- TGC AGA TCT CAA ATC TCT GG -3' PPAR-a-B: 5'- ATC ACA GAA GAC AGC ATG GC ±3' 374bp
PPARa-IST PPAR-a-A: 5'- TGC AGA TCT CAA ATC TCT GG -3' PPAR-a-IST: 5'- ATC ACA GAA GAC AGC ATG 330bp
GCC GTT CAG GTC CAA GTT TGC G -3'
PPARb-wt PPAR-b-A: 5'- TTC CAG AAG TGC CTG GCA CT -3' PPAR-b-B: 5'- CTG CCA CAA TGT CTC GAT GT ±3' 275bP
PPARb-IST PPAR-b-A: 5'- TTC CAG AAG TGC CTG GCA CT -3' PPAR-b-IST: 5'- CTG CCA CAA TGT CTC GAT GTA
GGA TGC TGC GGG CCT TCT T ±3'
234bp
PPARg-wt PPAR-g-A: 5'- TCT CTC CGT AAT GGA AGA CC -3' PPAR-g-B: 5'- TCT TTC CTG TCA AGA TCG CC -3- 660bp
PPARg-IST PPAR-g-A: 5'- TCT CTC CGT AAT GGA AGA CC -3- PPAR-g-IST: 5'- TCT TTC CTG TCA AGA TCG CCC 554bp
ACT GGA GAT CTC CGC CAA C-3'
IL-6-wt IL6-A 5'- CAC TGG CAG AAA ACA ACC TG -3' IL6-B: 5'- GGA CTG CAG GAA CTC CTT AA -3' 361 bp
IL-6-IST IL6-A 5'- CAC TGG CAG AAA ACA ACC TG -3' IL6-IST: 5'- GGA CTG CAG GAA CTC CTT AAG 319 bp
GTT CTG TGC CTG CAG GTT C -3'
IL-8wt IL8-A 5'- ACA AGA GCC AGG AAG AAA CC -3' IL8-B: 5'- CTC TCT TCC ATC AGA AAG CT -3' 277bp
IL-8-IST IL8-A: 5'- ACA AGA GCC AGG AAG AAA CC -3' IL8-IST: 5'- CTC TCT TCC ATC AGA AAG CT CAC 238bp
TCT CAA TCA CTC TCA CT -Y
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the same period of time. Application of the two different Dorithin
preparations was followed by UVB administration (36, 49.5, 63, 76.5,
90, 125, 150, 180 mJ per cm2). Radiation equipment consisted of a
Saalmann Multitester (Saalmann, Herford, Germany) emitting exclusively
UVB in the range 280±320 nm. Erythema was assessed visually at 24 h
after irradiation by two independent physicians and photo-documented.
RESULTS
Differential effects of PPAR activators on proliferation and
cytotoxicity HaCaT cells were exposed for 24 h with different
concentrations of PPAR activators and then tested for proliferation
(Fig 1A) and membrane integrity (Fig 1B). WY-14,643 showed a
dose-dependent decline of BrdU incorporation with a half-
maximal effect at 100 mM. Interestingly, the cytotoxicity as
estimated by lactate dehydrogenase release was only very
low, <6% at 400 mM. Clo®brate, as another activator of PPAR-
a, showed half-maximal inhibition of DNA synthesis at 400 mM.
Over a broad concentration range the cytotoxicity of clo®brate was
very low but increased rapidly between 400 mM and 800 mM to
54%. Beza®brate, a preferential activator for PPAR-b, inhibited
BrdU incorporation by about 50% at 400 mM and showed only
little cytotoxicity. At 800 mM about 10% of the cells showed
membrane defects.
UVB-mediated expression of in¯ammatory cytokines is
diminished by activators of PPAR-a The induction and
secretion of pro-in¯ammatory cytokines IL-6 and IL-8 in
nonstimulated and UVB-light-stimulated HaCaT cells in the
presence of various PPAR activators was followed by the reverse
transcriptase PCR technique and ELISA. Based on the results from
experiments regarding proliferation and cytotoxicity (Fig 1) two
concentrations of PPAR activators were tested. In cell-free
supernatants from nonstimulated cells the basal IL-6 level was at
the lower detection limit of the ELISA (»36 pg per ml) and was not
linearly altered by PPAR activators (Fig 2A). Irradiation by UVB
light alone caused upregulation to »2700 pg per ml (Fig 2B).
Treatment with UVB light in combination with WY-14,643 or
clo®brate suppressed IL-6 secretion to <30%. Beza®brate showed
no effect on IL-6 secretion. In cell-free supernatants from
nonstimulated cells the basal IL-8 level was approximately
1800 pg per ml (Fig 2C). Treatment with WY-14,643 and
beza®brate offered a moderate decrease of IL-8 secretion whereas
clo®brate at 400 mM induced a prominent reduction to <20%.
UVB light (150 mJ per cm2) caused an upregulation of IL-8 to
»3700 pg per ml (Fig 2D). PPAR-a activators WY-14643 and
clo®brate suppressed the UVB response to <60%. Beza®brate could
not reverse the UVB-mediated upregulation. In order to evaluate
the minimum dose of WY-14,643 that is able to suppress UVB-
mediated IL-6 release a broad concentration range was tested
(Fig 2E). Already at 25 mM WY-14,643 the UVB-mediated
upregulation was suppressed to 65% indicating the sensitive
responsiveness of PPAR-a. To exclude that physical properties
of PPAR activators contribute to the attenuated UVB response all
experiments were repeated with TNF-a as an inducer of pro-
in¯ammatory cytokines (see Fig 3A, B). Similarly to UVB
treatment, PPAR-a activators reduced the TNF-a-mediated
induction of IL-6 and IL-8. Experiments regarding the regulation
of IL-6 and IL-8 mRNA levels con®rm the results derived from
ELISA studies, suggesting that the measured effects are due to gene
regulation or mRNA stability (Fig 4).
PPARs are downregulated by UVB lightÐpartial rescue by
WY-14,643 Levels of PPAR mRNA were determined using
reverse transcriptase competitive multiplex PCR. First, cells were
irradiated with 150 mJ per cm2 UVB and incubated for 6 h. In one
set of experiments 200 mM WY-14,643 was additionally present.
cDNA derived from total RNA were subjected to reverse
transcriptase competitive multiplex PCR and coampli®ed with
different amounts of IST. In one set GAPDH, PPAR-a, and
PPAR-b transcripts were ampli®ed with the corresponding IST
(Fig 5A). In a second set GAPDH and PPAR-g wildtype
transcripts were coampli®ed together with IST for GAPDH and
PPAR-g (Fig 5B). The regulation of PPAR transcript levels under
UVB treatment is summarized in Fig 5(C). mRNAs of all three
PPAR subsets become markedly downregulated by UVB. The
mean PPAR-a level after UVB was 6% compared to control cells.
Likewise, mean PPAR-b levels were 20%, and 12% for PPAR-g,
compared to nonirradiated cells. If UVB irradiation was carried out
after 4 h pretreatment with 200 mM WY-14,643 the levels of
PPAR mRNA of all three subsets were increased. In particular, the
levels of PPAR-a and PPAR-b were signi®cantly elevated
compared to UVB light alone up to 37% and 96%, respectively.
Levels of PPAR-g showed no statistical signi®cance between UVB
light alone and the combination of UVB light and WY-14,643.
UVB light attenuates basal activity of PPRE The activity of
PPRE was detected 24 h post UVB irradiation. The measured
values of PPRE±®re¯y luciferase activity were related to the light
emission of the renilla luciferase constructs. As shown in Fig 5(D)
Figure 1. In¯uence of activators of PPAR on DNA synthesis and
cytotoxicity in HaCaT cells. Cells were cultivated for 24 h in the
presence of different concentrations (mM) of PPAR activators. (A) Cells
were exposed to BrdU for the last 4 h. Then cells were ®xed and
incubated with peroxidase-coupled anti-BrdU. The immune complexes
are detected by the subsequent substrate reaction (tetramethylbenzidine).
The reaction product was quanti®ed by measuring the absorbance at
450 nm using a scanning multiwell spectrophotometer (ELISA reader).
(B) The formation of lactate dehydrogenase in the cell-free culture
supernatant was taken as a measure for cell damage. All values were
related to a positive control (100%) in which cells were lyzed by
treatment with 1% Triton X-100. All values are related to control cells
without any treatment. Each bar represents the mean of four
independent experiments. The standard deviations are indicated.
Statistical analysis was performed using Student's t test: n.s., no
signi®cance; *p < 0.1, **p < 0.05, ***p < 0.01 versus untreated controls.
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Figure 3. WY-14,643 suppressed the TNF-a-
mediated release of IL-6 and IL-8. Cells were
treated with 10 ng per ml TNF-a for 24 h in the
presence or absence of WY-14,643. (A) TNF-a
alone caused upregulation to »487 pg per ml IL-
6. In the presence of WY-14,643 the IL-6
induction by TNF-a was diminished to <50%.
(B) IL-8 levels were massively induced by TNF-a
up to »10,400 pg per ml. The PPAR activator
WY-14,643 suppressed the TNF-a response to
<83%. Each bar represents the mean of four
independent experiments. The standard deviations
are indicated. Statistical analysis was performed
using Student's t test, with **p < 0.05 and ***p
< 0.01 versus TNF-a-treated controls.
Figure 4. Detection and quanti®cation of IL-
6 and IL-8 transcripts by reverse transcriptase
competitive multiplex PCR. Before UVB
irradiation cells were pretreated for 4 h with the
indicated PPAR activator. Six hours post
irradiation total RNA was isolated, transcribed
into cDNA, and used for multiplex PCR (for
details see Materials and Methods). (A), (B)
Representative agarose gels featuring the
regulation of IL-8 transcripts by PPAR activators,
by UVB light (150 mJ per cm2), and by the
combination of UVB light and PPAR activators.
Serial dilutions (1:3) of IST were coampli®ed with
the referring wildtype cDNA. (C), (D) Referring
results for IL-6 transcript regulation. The
calculated regulations are indicated at the bottom
of each set. Results are representative of three
different experiments. IST, internal standard; WT,
wildtype; Ctr, control; WY, 200 mM WY-14,643;
Beza, 400 mM beza®brate; UV, 150 mJ per cm2
UVB.
Figure 2. Activators of PPAR inhibit the
UVB-light-mediated release of IL-6 and IL-8
in HaCaT cells. Cells were pretreated for 4 h
with different PPAR activators at different
concentrations. Then the cells were irradiated
with 150 mJ per cm2 UVB light and the medium
was replaced by phosphate-buffered saline
containing PPAR activators. Consecutively, fresh
medium with the same amounts of PPAR
activators was added back to the cultures. After
total cultivation for 24 h cell-free supernatants
were used for ELISA. (A) In nonstimulated cells
PPAR activators show no linear effect on IL-6
secretion. The measured IL-6 levels are
approximately 36 pg per ml. (B) UVB irradiation
of 150 mJ per cm2 caused upregulation to
»2700 pg per ml. PPAR activators WY-14,643
and clo®brate suppressed the UVB response to
<30%. (C) The mean basal IL-8 reactivity was
»1800 pg per ml. The PPAR activators tested
showed suppression of IL-8; in particular,
clo®brate at 400 mM showed a prominent effect.
(D) UVB light at 150 mJ per cm2 caused an
upregulation of IL-8 to »3700 pg per ml. PPAR-
a activators WY-14,643 and clo®brate suppressed
the UVB response to <64%. (E) Treatment with
increasing concentrations of WY-14,643 caused a
dose-dependent suppression of UVB-induced IL-6
release. Already at 25 mM WY-14,643 the content
of IL-6 was reduced to 65%. Each bar represents
the mean of four independent experiments. The
standard deviations are indicated. Statistical analysis
was performed using Student's t test: n.s., no
signi®cance; *p < 0.1, **p < 0.05, ***p < 0.01
versus untreated and positive controls, respectively.
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the basal activity of PPRE was attenuated by UVB (150 mJ per
cm2) to approximately 30%. If irradiation was followed by
incubation with 200 mM WY-14,643 the UVB-induced
suppression of PPRE transactivation persisted. In summary, these
®ndings further substantiate the downregulatory effect of UVB on
PPAR or its heterodimerizing partner RXR, respectively.
WY-14,643 enhances the MED in human skin The anti-
in¯ammatory effect of the PPAR-a activator WY-14,643 was
tested by ®ve volunteers. Figure 6 shows a representative result.
The MED of a representative volunteer (MG) after treatment with
Dorithin was 36 mJ per cm2. After application of 5% WY-14,643
in Dorithin the MED increased to 76.5 mJ per cm2. Figure 7
shows the MED of the ®ve tested volunteers. A signi®cant increase
of MED values after application of WY-14,643 was observed. The
Figure 5. UVB light leads to decreased PPAR mRNA transcripts
and attenuates basal transactivation of PPRE. Levels of PPAR
transcripts were determined using reverse transcriptase competitive
multiplex PCR. Serial dilutions (1:3) of IST were coampli®ed with the
referring wildtype cDNA. (A) Reverse transcriptase competitive
multiplex PCR of GAPDH, PPAR-a, and PPAR-b. UVB irradiation
decreases PPAR-a and PPAR-b transcripts. (B) Reverse transcriptase
competitive multiplex PCR of GAPDH together with PPAR-g. UVB
irradiation diminished PPAR-g mRNA. (C) Summary of UVB-light-
induced impact on PPAR gene transcripts in the presence or absence of
200 mM WY-14,643 detected by using reverse transcriptase competitive
multiplex PCR assays. Pretreatment with WY-14,643 attenuated the
UVB-mediated downregulation of PPAR-a and PPAR-b transcripts. All
values were related to control values derived from untreated cells. Each
bar represents the mean of four independent experiments. The standard
deviations are indicated. Statistical analysis of the indicated data bars was
performed using Student's t test: n.s., no signi®cance; **p < 0.05. (D)
Cells were UVB irradiated and consecutively incubated in the presence
or absence of 200 mM WY-14,643 for 24 h. Finally, cells were lyzed and
tested for PPRE luciferase activity (see Materials and Methods). UVB light
attenuates basal transactivation to about 30%. This value was not altered
in the presence of WY-14,643 indicating a UVB-mediated decrease of
PPAR or RXR, respectively. Each bar represents the mean of three
independent experiments. The standard deviations are indicated.
Figure 6. The PPAR-a activator WY-14,643 reduces UVB-
induced erythema. Representative clinical picture of inner forearm
skin pretreated with or without WY-14,643 and consecutive UVB
exposure. The left half shows skin pretreated with the vehicle containing
5% (wt/wt) WY-14,643 whereas the right half shows skin pretreated
with the vehicle alone. The UVB doses range from 90 mJ per cm2 (top)
to 36 mJ per cm2 (bottom). The clinical picture was taken 24 h after
irradiation. The MED in skin treated with the vehicle alone was about
36 mJ per cm2. In skin pretreated with WY-14,643 the MED was
elevated to about 76.5 mJ per cm2.
Figure 7. MED testing on ®ve volunteers. MED testing was
performed on both volar forearms with and without PPAR-a activator
WY-14,643 in Dorithin cream: MED after application of Dorithin
cream alone (black dots) ranged from 36 to 76.5 mJ per cm2 (mean, 49.5
mJ per cm2). There was a signi®cant increase of MED values (white dots)
after application of 5% WY-14,643 in Dorithin cream (range, 76.5±180
mJ per cm2; mean, 124.3 mJ per cm2). Statistical analysis was performed
using Student's t test, with p < 0.01.
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elevation of the MED after pretreatment with WY-14,643 suggests
the use of PPAR-a activators in the prophylaxis of sunburn-
induced erythema.
DISCUSSION
Human epithelia provide the ®rst line of defense between the
organism and the external environment. Besides microbial and
chemical irritations, the irradiation of human skin by UVB light
presents a ubiquitous challenge. Exposure to UVB light is directly
coupled to the induction of speci®c pro-in¯ammatory cytokines,
including IL-6 (Urbanski et al, 1990; Petit-Frere et al, 1998) and IL-
8 (Kondo et al, 1993; Stein et al, 1997). The expression of IL-6
contributes to the acute-phase in¯ammatory response but is also
known to in¯uence the aging process (Ershler, 1993). The
chemokine IL-8 offers chemotactic properties for lymphocytes
and neutrophils, but also exhibits neoangiogenic properties (Koch
et al, 1992; Engelhardt et al, 1998).
In order to avoid an exaggerated in¯ammatory response the
organism has evolved mechanisms that control the duration of the
in¯ammatory response. An imbalance in this equilibrium with
uncontrolled in¯ammation can occur in septic and trauma patients
resulting in increased morbidity and mortality. Activation of
PPAR-a by the in¯ammatory mediator LTB4, a metabolite of
arachidonic acid, may counteract the in¯ammatory response by a
feedback mechanism inducing LTB4 catabolism (Devchand et al,
1996). Interestingly, LTB4 becomes photodegraded by exposure to
UVB light (Millar et al, 1989; Lehmann et al, 1992). In contrast,
prostaglandin E2 and prostaglandin F2-a are strongly induced by
UVB light (Pentland et al, 1990; Miller et al, 1994) but fail to offer a
signi®cant activation of any of the three PPAR subsets (Yu et al,
1995). There might be other yet unknown metabolites of
arachidonic acid that become induced by UVB light and serve as
physiologic activators of PPAR.
It has been shown that fatty acids contribute to in¯ammatory
control. The dietary supplementation of ®sh oil, which is rich in
w-3 polyunsaturated fatty acids, leads to a reduction of the sunburn
response. In particular, dietary ®sh oil attenuated UVB-induced
erythema sensitivity and prostaglandin E2 levels in UVB-irradiated
skin (Rhodes et al, 1995). As polyunsaturated fatty acids are strong
acivators of PPAR (Forman et al, 1997; Krey et al, 1997; Murakami
et al, 1999), an anti-in¯ammatory mechanism including the
activation of PPAR-a is therefore likely. In our study we used
synthetic compounds that preferentially activate PPAR-a or
PPAR-b. The mechanism by which these compounds lead to
PPAR activation is not yet fully understood. In vitro data have
demonstrated that ®brates cause conformational changes in the
PPAR protein (Forman et al, 1997; Krey et al, 1997), which
suggests a direct effect on the receptor. It has been proposed that
®brates induce accumulation of fatty acids, however, which in turn
act as endogenous PPAR activators through the indirect mechan-
ism of inhibiting carnitine palmitoyltransferase-I, a pivotal enzyme
in long-chain fatty acid transport into mitochondria (Eacho and
Foxworthy, 1988). Our study clearly demonstrates that activation
of PPAR-a by WY-14,643 or clo®brate inhibits the expression of
pro-in¯ammatory cytokines after UVB stimulation in vitro. These
®ndings were proved by showing the anti-in¯ammatory potency of
a PPAR-a activator in intact human skin.
In this work we give evidence of PPAR gene regulation by
UVB light. The massive downregulation of all three PPAR subsets
suggests a possible mechanism by which UVB light mediates
in¯ammation. The downregulation of PPAR-a mRNA was also
demonstrated after treatment with TNF-a (Beier et al, 1997).
Therefore, it seems likely that PPAR downregulation is a universal
response to a variety of pro-in¯ammatory stimuli. Interestingly, the
UVB-mediated downregulation of PPAR was partially abrogated
by the PPAR-a activator WY-14,643. Maybe the induction or at
least the stabilization of PPAR mRNA in the presence of an
in¯ammatory stimulus by PPAR activators itself represents a
mechanism counteracting in¯ammation. These ®ndings offer future
perspectives for treatment of in¯ammatory skin manifestations.
Topical or systemic application of PPAR-a activators or com-
pounds that positively regulate PPAR-a gene expression may help
to counteract exaggerated in¯ammatory processes. In particular a
prophylactic treatment with PPAR activators before sunbathing
may help to reduce the adverse effects of UVB.
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